• Flora closed a €2 million investment in Hoshi International Inc., fulfilling the earlier-announced LOI back in June 2021
• This move is set to capitalize on Hoshi’s strong European presence, its technical know-how along with its understanding of the European market
• Hoshi acknowledged the investment with the announcement that it would work together with Flora to bring to market finished product formats from Flora’s brand portfolio
• Flora referred to this investment as the first of many steps by the company to advance its plans to launch products across the world

On August 24, 2021, Flora Growth (NASDAQ: FLGC) announced closing a €2 million investment in Hoshi International Inc. It also announced that it had increased its fully-diluted ownership in Hoshi through a securities swap. When making the announcement, Luis Merchan, the President and Chief Executive Officer (“CEO”) of Flora, noted: “We are excited to increase our alignment with the Hoshi management team and believe the partnership will be much greater in scope than only using their Portugal and Malta facilities as a European importation gateway for our Colombian cannabis flower and derivatives” (https://ibn.fm/pTzKf). Earlier in June this year, Flora had announced signing a Letter of Intent (“LOI”) for planning to make an initial strategic equity investment into Hoshi. Flora termed this as “the first of many steps to advance its plans to launch Flora-branded products across the world” (https://ibn.fm/B9K8x). Having followed through with the investment, the company is now set to capitalize on Hoshi’s strong European presence. It is also bound to leverage the latter’s technical know-how, along with its understanding of the European market, to not only expand its market reach but also obtain its European Union Good Manufacturing Practices (“EU-GMP”) certification. John Aird, the CEO of Hoshi, noted: “We are excited to begin working alongside the Flora team and sharing our understanding of the European market while working together to bring to market finished product formats from Flora’s brand portfolio that are suitable for European medical consumers. He further added: “Not only has Flora made an investment into Hoshi, but through our securities swap, the Hoshi management team also has a vested interest in the success of Flora Growth and our long-term working relationship.” Flora’s €2 million investment came with the following terms:

• Flora would hold a right of first refusal to supply any cannabis oil or derivative products acquired by Hoshi or any of its affiliates at the processing facility in Malta. This will be subject to the parties entering into a definitive agreement by October 1, 2021
• Flora would be Hoshi’s preferred supplier of genetic material and finished cannabis derivative products at its cultivation and processing facility in Portugal, subject to the two parties entering into a definitive agreement by October 1, 2021
• Flora would be entitled to nominate one Director to Hoshi’s Board of Directors, specifically Luis Merchan, Flora’s President and CEO
• Hoshi will use commercially reasonable efforts to grant Flora access to its EU-GMP auditors to assist Flora to obtain EU-GMP certification at its Cosechemos cultivation and extraction facility in Colombia

Hoshi is a fully integrated cannabis company that focuses on the European market. Its team comprises renowned cannabis entrepreneurs, hence its focus on developing and operationalizing assets across the global cannabis industry. Hoshi’s focus and emphasis are on cultivating, manufacturing, and distributing cannabis products throughout the EU. So far, the company is uniquely positioned to become the leading provider of cannabis and derivative products for this budding European market. On the other hand, Flora is a cannabis cultivator, processor, and brand builder with a focus on the international market. It has made a name for itself by leveraging natural and cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including pharmaceuticals, hemp textiles, cosmetics, and food and beverage. Flora currently operates one of the world’s most extensive outdoor cultivation facilities, intending to market a higher-quality premium product at below-market prices. 2020 was a big year for the European medical cannabis industry. Germany’s imports of certified flower for medical purposes reached 9,231 kg, according to the Federal Institute for Drugs and Medical Devices. Between January and September 2020, the value of medical cannabis transactions in Germany alone amounted to €111 million, with flower sales accounting for 48.6% of these sales. Prohibition Partners has even projected that by 2024, over one million German patients will have access to medical cannabis, making Germany the leading European cannabis market in terms of growth. It is further projected that the German medical cannabis market will be worth €7.7 billion by 2028. By the end of 2021, it is estimated that the entire European cannabis market will be valued at €403.4 million. By 2025, this industry is set to be valued at €3.2 billion, representing a compound annual growth rate (“CAGR”) of 67.4% between 2021 and 2025. Flora hopes to capitalize on Hoshi’s understanding of and presence within the European market to capitalize on its strategic growth plans. Closing this investment is a step in the right direction and a first in Flora’s overall expansion plan to venture into the European market for its cannabis products. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Drug delivery technology innovator Lexaria Bioscience is celebrating the positive outcomes of clinical testing of its trademarked DehydraTECH platform for reducing the blood stream delivery time of anti-virals, NSAIDS and potential hypertension treatments
• Lexaria will participate in H.C. Wainwright’s annual Global Investor Conference this month to help bring further attention to its successes
• The DehydraTECH technology enhances the delivery of pharmaceuticals that can be administered orally, and testing has shown no adverse chemical compounds have been created in the process
• The COVID-19 pandemic has raised the profile of the anti-viral medication market, enhancing the opportunities for Lexaria’s revenue stream

As life sciences technology innovator Lexaria Bioscience (NASDAQ: LEXX) takes a leap forward in R&D programs demonstrating the effectiveness of its trademarked oral substance delivery platform, the company is preparing to join other participants in the 23rd annual Global Investor Conference hosted by full-service investment bank H.C. Wainwright & Co. The investor conference scheduled Sept. 13-15 will be a hybrid online and in-person gathering of companies enjoying opportunities for platform presentations, one-on-one meetings with investors, and networking with other attendees (https://ibn.fm/TiS8V). Lexaria’s CEO, Chris Bunka, will be making the company’s presentation, which will be available to attendees on Monday September 13th. Lexaria’s recent strides in developing and testing its oral delivery platform DehydraTECH include its successful 2021 antiviral drug program, which has produced data showing DehydraTECH can enhance antiviral drugs’ ability to reach the bloodstream so that they can safely and more effectively do what they are designed to accomplish. DehydraTECH processed substances such as pharmaceutical drugs enhance their bioavailability, and the clinical trials have also demonstrated that DehydraTECH does not alter nor degrade the drug molecules chemically as to create new molecular entities (“NMEs”) that would create new regulatory concerns for the finished products (https://ibn.fm/VWWld). H.C. Wainwright has a history of leading investment transaction volumes ranked by market research service PlacementTracker. Wainwright has consistently placed first among investment banks for confidentially marketed public offerings, registered direct and private placement transactions, according to the analysts (https://ibn.fm/lG6DA). The September event will include a panel discussion with former Food and Drug Administration Commissioner Scott Gottlieb (2017-2019), who is a member of the board of directors of drug maker Pfizer, Inc., and is preparing to roll out his long-awaited book, “Uncontrolled Spread: Why COVID-19 Crushed Us and How We Can Defeat the Next Pandemic,” this month. The antiviral medication market has gained particular attention during the ongoing COVID-19 pandemic, and Lexaria’s DehydraTECH is in a position to potentially bring in significant revenues in partnership with the antiviral medications as well as NSAIDs and products that target hypertension and alternative nicotine products — an opportunity the company has been mindful of. The potential for using DehydraTECH in conjunction with cannabidiol (“CBD”) to target hypertension is one of the sectors of Lexaria’s research gaining attention following the results of a recent study showing DehydraTECH-processed CBD generated a rapid and sustained drop in blood pressure among study participants (https://ibn.fm/AZQYS). “Lexaria was also pleased that its DehydraTECH-CBD was well tolerated by all subjects, with no serious adverse events or side effects observed or reported. Ingestion of the concentration-matched, generic CBD control, on the other hand, resulted in unwanted side effects in some of the volunteers,” the company’s news release states. “These findings corroborate what Lexaria has previously evidenced in other unrelated studies whereby human volunteers have also experienced reduced side effects with DehydraTECH-processed test articles compared to concentration-matched, generic controls.” A second human clinical hypertension study of DehydraTECH’s capabilities is under way, and a third study is planned this year once the results of the first two studies are carefully evaluated and considered. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Tryp Therapeutics is set to present at the H.C Wainwright 23rd Annual Global Investor Conference scheduled for Sept. 13-15, 2021
• Greg McKee, company chairman and CEO, will provide an overview of the business and its pipeline, including the Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program
• Tryp’s presentation will be available on-demand from 7.00 a.m. EDT on Sept. 13
• Through the PFN program, Tryp is focused on developing psychedelic compounds targeting diseases with high unmet medical needs, such as chronic pain conditions and eating disorders

As a company at the forefront of the psychedelic renaissance, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has differentiated itself by focusing on what most psychedelic drug development companies are not. Guided by an exceptional roster of scientific advisors and an experienced management team led by Tryp chairman and CEO Greg McKee, Tryp is developing psychedelic compounds targeting diseases with high unmet medical needs through its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program. The PFN program, which features TRP-8802 as the lead drug candidate and TRP-8803 as the proprietary formulation with a novel method of administration, targets chronic pain conditions, including fibromyalgia, phantom limb pain, complex regional pain syndrome and others, as well as eating disorders such as hypothalamic obesity, binge eating disorder and others. Tryp intends to proceed directly into Phase 2a human trials by leveraging existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802 and TRP-8803. To this end, it has partnered with leading academic institutions that have indication-specific expertise needed for the trials. Tryp has also entered into an agreement with a contract development and manufacturing organization (“CDMO”) for the research, development and GMP manufacturing services for synthetic psilocybin that will form the basis of the PFN program. It has further engaged another CDMO to develop the analytical methods and final formulations of its TRP-8802 and TRP-8803 products (https://ibn.fm/FUSJx). According to a recent press release, the company will present at the conference, with Greg McKee providing an overview of the business and its pipeline updates, including the PFN program. Tryp’s presentation will be available on-demand starting at 7:00 a.m. EDT on Sept. 13 (https://ibn.fm/F5YQU). Founded in 2019 and headquartered in San Diego, California, Tryp Therapeutics has made significant progress that positions it favorably in the promising psychedelic medical market. It is also similarly poised to leverage growth opportunities spanning multiple therapeutics markets, in line with its commitment to lead the next wave of psychedelic drug development beyond mental health. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• Company is committed to providing products based on formulations driven by solid scientific research
• Simply Sonoma is creating three tiers of products
• The company is developing products in four areas: the sleep aid market, the pain and inflammation sectors, the probiotic space, and the beauty and skin segments

In a CBD market becoming ever more crowded, Simply Sonoma is preparing to launch a line of CBD products that is truly distinctive. The company, which is also in the midst of a SEC regulation CF offering, is creating unique medicinal hemp strains that are alternatives to traditional, chemically manufactured offerings. Specifically, the company is committed to providing products based on formulations driven by solid scientific research (https://ibn.fm/bMBJ7). Simply Sonoma also works to educate consumers by providing relevant, timely information, including appropriate dosage levels. In addition, the company is looking beyond the traditional CBD offerings of gummies and tinctures, instead eyeing unique and different product options, such as CBD-infused organic apple juice and alcohol-free wine beverages. Initially, Simply Sonoma is planning on three tiers of products: organic CBD formulations for consumer medicinal applications; organic whole-plant extracts of CBD and cannabinoids that provide the whole-plant synergistic effect and offer a dose response for a variety of diseases; and organic extracts paired with traditional over-the-counter functionality that are designed to deliver all the benefits of traditional OTC products but are organic and plant derived for a more natural healthy approach, minimizing synthetic chemical components and adverse effects. In addition to its keen sensitivities to the most promising products, Simply Sonoma is also deeply aware of the best opportunities for growth and success. The company plans to develop products in four main areas: the global sleep aid market, which reached an estimated $175 billion last year; the joint and bone pain sectors, which are projected to top $41 billion by 2026; the probiotic space, which is forecast to reach $65 billion by 2023; and the beauty and skin segments, which totaled $380 billion in 2019. With its key differentiators already in place as a solid strategy backdrop, Simply Sonoma is projecting a five-year financial plan that shows gross revenues from these four segments reaching an estimated $15.5 million. Those numbers can only strengthen the company’s CF offering, which notes that Simply Sonoma is laser focused on providing the purest, organically grown products possible. The company does this by using CBD obtained direct from the farm with as little processing and manipulation as possible. In addition, Simply Sonoma principals have years of farming experience, as well as a history as scientists in the biotech industry. Simply Sonoma is a different kind of natural company. From seed to sale, it owns or contracts the organic grow, extraction and product formulation operations. The company has been developing products since 2017 based on scientific research and data and has several ready to launch. Its nationally available, organic CBD products utilize the company’s own unique formulations. For more information or to invest in Simply Sonoma, visit the company’s website at www.SimplySonoma.org. NOTE TO INVESTORS: The latest news and updates relating to Sonoma are available in the company’s newsroom at https://ibn.fm/Sonoma

• Investor appetite in Africa continues to be robust, attracting $407 billion of Foreign Direct Investments (“FDI”) between 2014 and 2018
• Agriculture makes up 23 percent of sub-Saharan Africa’s GDP and 60 percent of employment
• Tingo directly benefits the African economy by helping farmers gain better prices for their crops
• The company enables more efficient markets via greater distribution of agricultural products
• Tingo directly provides an access point to technology for tens of millions of Africans
• The company is expanding into fintech banking services for the mass market, providing access to financial services through Tingo Pay, its proprietary mobile wallet application

Tingo (OTCQB: IWBB) is a digital service agri-fintech technology company focused on foundation-level agriculture and related financial services in Africa. The company aims to be Africa’s leading agri-fintech player, transforming rural farming communities to connect through its proprietary platform to meet their complete needs – from inputs and agronomy to off take and marketplace – and deliver sustainable income in an impactful way. The company’s vision is to build complete digitally inclusive ecosystems that promote financial inclusion and deliver disruptive micro-finance solutions, empower societies, produce social upliftment in rural communities and open international opportunities. Tingo believes that a truly connected world will help contribute to a better global society. The company’s core focus areas are telecoms, financial services/fintech and agritech. Tingo’s goal is to provide a best-in-class customer experience, support the domestic economies of its host countries and support technological and financial inclusion to end the poverty premium. Through this, Tingo hopes to deliver attractive returns to shareholders while investing in the long-term future of the company and its subsidiaries. Global climate change is challenging sustainable production and food security. Tingo’s strategy and market execution provide an opportunity for Africa to be a core focal point to solve a number of key areas of concern, including food security, gender equality, financial inclusion and poverty alleviation, to name a few. Disruption of micro finance through the use of DeFi-based stable coins and smart contracts will give agri-communities access to capital markets-driven digital finance solutions that make them more competitive and sustainable economically, striking a good balance of returns between digital asset providers and Tingo as the service partner. This innovation will deliver significant access to much needed finance at ‘Grassroot’ levels, delivering tangible social upliftment and GDP growth in the African markets served by Tingo. Tingo Mobile, with more than nine million subscribers, is Nigeria’s leading technology and device-as-a-service platform aimed at accelerating digital commerce, especially in the country’s agritech and fintech verticals. The company helps farmers acquire mobile phones through a unique leasing plan, connecting them to mobile and data networks through its own virtual mobile network. Tingo also connects farmers to markets, services and resources via Nwassa, its digital agritech marketplace platform that commenced operations in 2020. The company has also launched a beta version of TingoPay – a B2B and B2C fintech app aimed at providing financial services to users inside and outside of the agriculture value chain. Among the services offered are mobile wallets, payment processing and access to specialist lenders, insurers and pension products. Tingo will soon announce its innovative blockchain-based solution for use of digital stable coins to empower frictionless trade across borders in Africa. The company’s market-proven model in Nigeria is its core foundation, enabling Tingo to deliver the same service model across Africa to become the continent’s leading agri-fintech business powered through smartphone technology. The African Continental Free Trade (“ACFT”) plan will be a key framework to prepare the company to be the leading intra-Africa trading hub for trade flows across Africa in the medium term, when it is likely the agreement will be executed into tangible activity. Tingo is well positioned to easily transform the goals of the ACFT into reality when finally implemented by the African Union and the various African countries that have not signed up. Tingo posted total revenue of $594 million in 2020, with $212 million EBITDA. As of December 31, 2020, Tingo has 9,344,000 subscribers. The company is confident that these figures will grow through its expansion across Africa and natural progression of business in Nigeria. Businesses Tingo has four core businesses:

• Mobile Phone Leasing – Tingo has distributed almost 30 million mobile handsets since 2014 and will continue to replace the devices of its installed customer base every three years. Tingo Mobile provides the latest mobile phone handsets at an affordable price point and allows customers to spread payments over 36 months.
• Mobile Voice and Data Service – Through a mobile virtual network, Tingo provides its customers with voice and data services, allowing customers to communicate effectively, both inside and outside the agricultural ecosystem.
• Nwassa Marketplace Platform – Nwassa is Tingo’s proprietary agritech platform which provides Africa’s farmers with access to global markets to secure more competitive pricing for their crops. The platform processes 500,000 daily transactions with a value of over $8 million. A select group of trusted partners can assist smallholder farmers and agricultural cooperatives with packaging, warehousing, and dry and wet cargo logistics, as well as up-to-date information from the global agricultural sector. Tingo provides its customers with digital wallet services, which enable them to send and receive domestic payments, monitor cash flow in real time and securely hold money. The company also provides access to other services, such as utility bill payment, virtual airtime top-up, insurance services and alternative lending solutions.
• TingoPay – Since the launch of the Nwassa platform, Tingo has been a dominant player in the B2B fintech vertical. After many successful months of operating Nwassa, Tingo entered the fintech B2C vertical to extend its B2B offering to a broader market beyond agriculture.

TingoPay is still in its beta phase and will launch in 2021 with a comprehensive marketing campaign. TingoPay offers the following services:

• Tingo Wallet top-up
• Peer to Peer payments, inclusive of merchant payments at the stores
• Utility payments – airtime, broadband, cable, electricity, water, hotel, flights etc.
• Pension payments
• QR code payment services

Market Opportunity Africa is the second-largest continent by population. It is also the youngest by far, with a median age of 18 for its 1.3 billion people. Tingo believes the building blocks for growth in Africa’s agriculture industry are in place and that the company is well positioned to participate in the upside. Sub-Saharan Africa’s population is growing at a rate of 2.7 percent per year. At the current growth rate, the continent’s population will double by 2050. Africa’s youthfulness represents a significant opportunity for material growth in demand for agricultural commodities. This younger generation is also being born into a digital world and is comfortable using technology. Africa’s governments are improving business conditions for entrepreneurs and small businesses. Sub-Saharan Africa’s World Bank Doing Business rank has improved from 45 in 2004 to 65 in 2020. Tingo believes this trend will continue and encourage establishment of more new ventures across all economic sectors, including agriculture. Africa attracted $407 billion of Foreign Direct Investments (“FDI”) between 2014 and 2018. Investments are increasingly focused on services and industrial sectors. Only 20 percent of investments are in extractive industries – a clear reversal from 2008, when 55 percent of FDI was aimed at resource extraction. Tingo believes FDI into Africa will help resolve significant infrastructure constraints and create value for agribusiness. Management Team Dozy Mmobuosi is the CEO of Tingo. He cofounded Tingo Mobile PLC (Nigeria) in 2001 and led the design and launch of Nigeria’s first SMS banking solution, which is still in use in the country today. He also headed a team of more than 120 Chinese and Nigerian engineers in the construction of two mobile phone assembly plants in Nigeria, which have produced and distributed 20 million phones across the country. He has led Tingo’s growth to more than $600 million in revenue annually. He holds a Ph.D. in Rural Advancement from UPM Malaysia. Dakshesh Patel is the CFO of Tingo. He was formerly CFO of NatWest’s Global Debt and Investment Banking division. He has served as a Director at Gerken Capital Associates, a San Francisco-based alternative asset fund manager. He also led the restructure of Lloyds Banking Group (last financial crisis); managed integration of two leading shipping groups’ global treasury function to create world-leading shipping group Maersk Shipping; built three fintech companies; and exited one to Worldpay. Mr. Patel has strong banking experience, with a focus on Africa. He is a chartered accountant. Chris Cleverly is president of Tingo. He has served as CEO of the Made in Africa Foundation, and as CEO of blockchain payments gateway startup Kamari. He has been a board member of several companies, both public and private, in the UK, India, China and Africa. He has advised multiple UK companies on their entrance into African markets, and regularly advises the UK Government on development issues and African governments on investment issues. Clarence Simms is the Chief Technology Officer at Tingo. He has 25 years of IT and IT management experience. He has worked in IT Shared Services Technical Operations and IT Program Management for Huawei Technologies and MTN. As an entrepreneur, he created Africaprepay.com, a service that allows African Diaspora travelers to send airtime, pay bills, send mobile money and transfer money to a bank account from anyplace in the world. Rory Bowen is the Chief of Staff at Tingo. Mr. Bowen started his career in traditional capital and derivatives markets working for Moneycorp and Tradition UK in European and emerging markets across FX, interest rate derivative and government bond markets. He has also spent time with one of Europe’s fastest growing fintech’s banking circles. Before joining Tingo, he was Chief of Staff at FinTech Alliance, an organization established in partnership with the UK Government Department for International Trade to foster innovation, growth and foreign direct investment (“FDI”) in the financial services sector and facilitate greater public/private cooperation. For more information, visit the company’s website at www.TingoGroup.com. NOTE TO INVESTORS: The latest news and updates relating to IWBB are available in the company’s newsroom at https://ibn.fm/IWBB

• AnPac Bio-Medical Science Co., Ltd. held its 2021 technical symposium, entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment” in Shanghai, China, on August 6, 2021
• The symposium included attendees from various hospitals, universities, and Fortune 500 companies, including Thermo Fisher Scientific and AnPac Bio’s contract partner Roche Pharmaceuticals China
• A recent report from Frost & Sullivan ranked AnPac Bio at #3 in the world and 1^st  in China for the number of clinical samples analyzed amongst companies that offer next-generation early cancer screening and detection technology

AnPac Bio-Medical Science (NASDAQ: ANPC) recently held its 2021 technical symposium entitled “The Applications of Biophysical Technology in Cancer Prevention and Treatment.” The symposium was held in Shanghai, China, and was attended by life science Fortune 500 companies such as Thermo Fisher Scientific and Roche Pharmaceuticals. Experts came together to discuss emerging cancer prevention and treatment theories and technologies, including the applications of biophysical technology to address these needs. Measurement of biophysical properties is the basis for Anpac Bio’s novel CDA technology. The Company’s CDA technology can rapidly detect 26 different types of cancers with a simple blood test. Talking points of the symposium included the newly announced cooperation between AnPac Bio and Roche Pharmaceutical China, as well as Thermo Fisher Scientific’s latest developments in in-vitro diagnosis (“IVD”), and the clinical trials that have been held on AnPac Bio’s proprietary cancer differentiation analysis (“CDA”) technology, including recently unblinded and analyzed clinical data. AnPac Bio is one of the first companies in the world to produce major theories and methods of multi-level, multi-parameter, and multi-cancer screening. The innovative technology has opened up a new field in early cancer screening that is based on a biophysical properties and has achieved significant results. In 2019, Frost & Sullivan ranked AnPac Bio third in the world and first in China among those companies in the region in terms of the number of clinical samples offering next-generation early cancer screening and detection. With one of the largest sample libraries in the world and more than 220,000 samples tested, AnPac Bio is an innovative leader in the field. The company’s CDA technology has shown to be advantageous over traditional detection methods, allowing it to outperform in the early detection market. The company’s main goal for 2021 is to extend its major discoveries in the field of early cancer detection and also develop cancer treatment technologies. “This technical symposium allowed people to better understand the most cutting-edge applications of biophysical technology in cancer prevention and treatment, and it also played an important role in promoting future research and development in cancer prevention and treatment,” Dr. Chris Yu, CEO and Chairman of AnPac Bio, said. “As a pioneer in the application of biophysics to cancer prevention and treatment, AnPac Bio continues to report new ideas and cutting-edge technology to the public, sharing the latest clinical study and trial results, and continuing to promote collaborations between industry, and academia.” AnPac Bio has proven to be an early thought leader and developer of multi-cancer (also called pan-cancer) ideas and technology. The company’s patent applications and IP began in the early 2010’s, and by 2014 it had already announced a cancer screening product with the capability of screening 16 types of cancer earlier than anyone else in the industry. AnPac Bio’s CDA technology combines the assessment of existing biomarkers with the biophysical properties and cellular proteins that signal the lead up to serious health conditions (including cancer). The technology can also be used to pinpoint the most likely location for cancer or predict where the risk will be high in the future. Having invented and championed the idea and method of “multi-level, multi-parameter” cancer screening, AnPac Bio’s contributions are now recognized and accepted by leading United States medical institutions and life science companies. For more information, visit the company’s website at www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

• Lexaria Bioscience Corp. and its patented DehydraTECH technology promote a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro, and human clinical testing
• DehydraTECH is sub-licensed to other companies in select countries, and is in close collaboration with the largest R&D organization in Canada, the National Research Council, since January 2017
• The technology is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter (“OTC”) capsules, pills, tablets, and oral suspensions
• DehydraTECH-enabled drugs offer multiple benefits, including faster delivery, increased bioavailability, increased brain absorption, improved drug potency, reduced administration costs, and masking unwanted taste without the use of additional sweeteners.

As an innovator of drug delivery methods, Lexaria Bioscience (NASDAQ: LEXX) and its patented DehydraTECH are improving the speed and efficiency of orally delivered fat-soluble active molecules and drugs. Lexaria Bioscience is advancing its IP for transforming existing consumer products and medications that may improve availability and bioavailability. DehydraTECH promotes a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro, and human clinical testing. Lexaria Bioscience operates four subsidiary companies focused on different commercial opportunities within their respective industries – Lexaria Pharma Corp., Lexaria Nicotine Corp. (16.67% owned by Altria Ventures Inc.), Lexaria Hemp Corp., and Lexaria Canpharm Corp. The DehydraTECH technology is also sub-licensed to other companies in select countries. The Company also has a collaborative research agreement with the National Research Council (“NRC”), Canada’s premier research and technology organization. Lexaria Pharma Corp. – investigates new products for high blood pressure (hypertension), antiviral therapy, and other drug classes. Lexaria Nicotine Corp. – investigates oral non-combusted tobacco-derived nicotine product formats. Lexaria Hemp Corp. – pursues business-to-business (“B2B”) opportunities, with cannabinoids like cannabidiol (“CBD”). Lexaria Canpharm Corp. – operates a state-of-the-art Health Canada-licensed laboratory that can develop novel psychotropic cannabinoid formulations for commercialization in sectors where it is federally legal. The DehydraTECH technology is suitable for use with a wide range of product formats. These include pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter (“OTC”) capsules, pills, tablets, and oral suspensions. The technology was specifically designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients into a more easily absorbable format, allowing them to enter the bloodstream more quickly and effectively. The use of DehydraTECH-enabled drugs or consumer products offers the following benefits:

• Speeds up delivery: effects can be felt by consumers in a matter of minutes
• Increases bioavailability: more effective at delivering drug or product into the consumer’s bloodstream
• Increases brain absorption: animal testing has suggested significant improvement in the quality of the drug delivered across the blood-brain barrier
• Improves drug potency: more of the ingested product is made available to the body, requiring lower dosages to achieve the desired effects
• Reduces drug administration costs: lower dosages mean overall lower drug costs
• Masks unwanted taste: technology eliminates or reduces the need for sweeteners

Since 2016, DehydraTECH has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to five to ten times, reducing the onset time from one to two hours to just minutes – masking unwanted tastes. The technology will be further evaluated for additional orally administered bioactive molecules, including antivirals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), and nicotine. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Sustainability cultivator Ideanomics has reached an agreement with commercial EV vehicle manufacturer VIA Motors to acquire VIA in an all-stock transaction valued at $450 million
• The VIA acquisition will solidify Ideanomics’ position as a made-in-America brand focused on building an end-to-end commercial EV ecosystem
• Ideanomics has completed other M&A activity in recent months designed to establish sustainable solutions that reduce the harmful effects of pollutants on the earth’s climate, particularly involving wireless battery-charging technology for commercial fleets
• The acquisition will help VIA to focus on completing the manufacturing process, with vehicles expected to roll out by 2023

New York-based Ideanomics (NASDAQ: IDEX) has been making a name for itself as a commercial electric vehicle (“EV”) industry innovator and on Aug. 30 the company announced an agreement it expects to be “transformative” in Ideanomics’ pursuit of providing end-to-end services for the commercial EV market. Ideanomics’ planned 100 percent acquisition of Utah’s VIA Motors International, Inc. in an all-stock transaction is expected to grant Ideanomics a vehicle manufacturing element to complement its charging technologies for “an immediate leadership position in a rapidly growing market” and deliver another revenue path to growth and profitability, Ideanomics CEO Alf Poor said in a morning conference call before market opening Aug. 30. “With Via we’re going to make the vehicles. Through our forced induction charging system with WAVE we’re going to be able to charge [them], through our relationship with [Germany’s Prettl Electronics Automotive] we’re going to be able to have outside battery storage to charge any type of fleets outside of a normal grid, and many other aspects, [to create a] complete ecosystem for Ideanomics,” Board Executive Chairman Shane McMahon said during the conference call (https://ibn.fm/3jcXs). Via will make electric commercial vehicles including Class 2 through Class 5 cargo vans, trucks, and buses. The company’s CEO is Bob Purcell, who led the General Motors (“GM”) electric vehicle business in the 1990s and is known as “the father of the legendary GM EV1,” which was the first mass-produced EV. “We were the car that started it all. … I was very proud of my group,” Purcell said in a Barron’s interview about the deal (https://ibn.fm/7lT7v). “We invented that technology … things like torque vector control for motors, battery management systems…none of that existed before the EV1.” The agreement cements Ideanomics as a made-in-America brand and values VIA at $450 million, according to the news release announcing the agreement (https://ibn.fm/lS950). Poor told investors during the conference call that revenue forecasts for the acquisition will be announced in the near future as part of the proxy for shareholders. Under the terms of the agreement, VIA shareholders will receive about 162 million shares of Ideanomics common stock after the application of certain purchase price adjustments, leaving VIA shareholders with ownership of about 25 percent of the combined company. Ideanomics is separately advancing $50 million of financing to VIA in the form of a secured convertible note, according to the news release. Production is planned for 2023, according to Barron’s. “What they needed was a partner that could help them, allow them to focus on execution. Because execution is going to be the difference between who gets market share and who doesn’t,” Poor said. For more information, visit the company’s website at www.Ideanomics.com. NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at https://ibn.fm/IDEX

• Tryp Therapeutics is a pharmaceutical company focused on establishing new drug candidates that will provide effective alternatives to established treatments for responding to medical conditions with largely unmet needs
• The company is preparing to launch a clinical trial with a 25mg synthetic psychedelic drug candidate, TRP-8802, to determine its efficacy and safety in treating select eating disorders in combination with psychotherapy
• Tryp recently announced that its educational partner, Fluence, has completed training of the psychotherapists who will be involved in administering the drug candidate to help establish minimal variability in the data outcomes and grant the patients the best possible experience
• Investment banking services provider, Ladenburg Thalmann & Co., announced on Aug. 26 that it has initiated coverage on Tryp with a “buy” rating

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is approaching the launch of its phase 2a clinical trial that will use synthetic psilocybin (a psychedelic drug derived from certain mushrooms) in combination with psychotherapy for a select class of overeating disorders. Tryp has continued to execute on its mission to develop successful treatments with increased efficacy for medical conditions with high unmet needs. The phase 2a trial, to be conducted at the University of Florida (“UF”), will determine safety and efficacy of psilocybin on hyperphagia — a condition in which the patients never feel full, so they are continually wanting to eat. “The research we’re actually going to be doing at the University of Florida with psilocybin is focusing on a little bit more intense problems than just eating disorders,” said pediatric eating disorders expert Dr. Jennifer Miller, who will be the trial’s principal investigator, during an interview with The Dales Report in May (https://ibn.fm/XDAVY). “Ultimately, of course, we hope it will help people with overall eating disorders, but first we’re going to focus on people with specific neurologic causes of those eating disorders … for treatment of a select chronic eating disorder called Prader-Willi Syndrome (‘PWS’).” The hyperphagia trial will also target hypothalamic obesity eating disorder — the result of the removal of a brain tumor — and binge eating disorder. TRP-8802, an off-the-shelf synthetic psilocybin active pharmaceutical ingredient (“API”) will aim to shake up the clinical thinking on how to deal with such neurological conditions and prepare Tryp for further studies using their novel, trademarked drug candidate, TRP-8803. “All of the currently available approved obesity and eating disorder medications are daily medications: you stop taking them, you stop having the efficacy,” Miller said. “Our hope is with psilocybin, … (that) once- or twice-a-year treatments will allow these neural networks to rewire themselves and provide a more chronic treatment, which doesn’t exist right now. … None of the currently available treatments or even past available treatments touch their appetite and fullness.” On Aug. 24, Tryp announced that psychedelic therapy educational platform partner Fluence, has completed the training of the psychotherapists who will be involved in the phase 2a trial by assisting and overseeing dosing sessions of the psychedelics (https://ibn.fm/eCpNN). “Psychotherapy is an integral part of Tryp’s novel treatment methods to create the proper mindset for the neuroplasticity benefits of psilocybin to take full effect,” the news release states. “Participants will undergo preparatory psychotherapy sessions with trained therapists leading to two dosing sessions in the upcoming phase 2a clinical trial for eating disorders. … Following the administration of the drug, patients will also benefit from multiple integration sessions with the therapists.” To ensure the scientific viability of the trials, it is important to establish definitive guidelines and training to minimize variability and grant the patients the best possible experience. The training will also be adapted to subsequent clinical trials, such as using Tryp’s API to treat fibromyalgia and other chronic pain indications. Tryp’s efforts have caught the attention of investment banking and capital markets products and services provider Ladenburg Thalmann & Co. Inc., which serves investors who are specifically focused on health care and life sciences companies. Ladenburg Thalmann announced on Aug. 26 that it had initiated coverage on Tryp with a buy rating (https://ibn.fm/9aFSD). In its research note, Ladenburg noted that psychedelics have recently outperformed approved prescription treatments for major depressive disorder and posttraumatic stress disorder, leading to the advisement that psilocybin-assisted psychotherapy may provide an appropriate response for helping people with eating disorders “benefit from a disconnect of the brain’s neural connections, allowing for new connections and behaviors distinct from current memories and feelings.” For more information on Tryp Therapeutics, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• AmpliTech posted $1,024,410 in total revenue for Q2’21, a 55% increase from the same period in 2020
• It also announced having paid off $1 million in debt while securing $0.2 million in SBA loan forgiveness
• The company also purchased $0.4 million worth of scientific equipment to enhance product development and testing
• The first half of 2021 also saw AmpliTech complete its financial recapitalization and Nasdaq up-listing, thereby realizing a working capital of $29.8 million
• All these achievements are positioning AmpliTech as the key infrastructure provider that supports 5G, satellite and other radio frequency communications infrastructure globally

On August 16, 2021, AmpliTech Group (NASDAQ: AMPG) announced its financial results for the second quarter of 2021 along with the first six months of the 2021 fiscal year (“Q2’21 and 6M’21”). Additionally, the company reviewed its growth outlook, its strides thus far, and some of the key milestones it achieved in the first half of 2021 (https://ibn.fm/7BCnP). Most notably, the company posted a 55% Q2’21 revenue growth compared to Q2’20. Total revenue stood at $1,024,410, up from $660,669 during the same period in 2020. This also represented a 117% growth from Q1’21. AmpliTech also reported that its order backlog as of the date of the announcement was $2.45 million, all in contractual hardware and engineering services, anticipated for delivery over the next three to six months, as opposed to $2.4 million at the close of Q1’21 (https://ibn.fm/7BCnP). The first six months of 2021 were significant for AmpliTech. For starters, the company completed its financial recapitalization and Nasdaq up-listing. This move allowed it to raise working capital of $29.8 million as of June 30 (https://ibn.fm/588HQ). This capital would go into product development, sales and marketing infrastructure investments while also offering the financial strength needed to engage with global customer prospects that were previously out of the company’s reach. As of the close of the first half of the year, the company had paid $1 million in debt and secured $0.2 million in SBA loan forgiveness. AmpliTech also reported having purchased $0.4 million worth of scientific equipment that was meant to enhance product development and testing (https://ibn.fm/7BCnP). It also made a significant strategic investment in its secure LNA chip development joint venture partner SN2N. AmpliTech is an enterprise that designs, develops and manufactures customer radio frequency (“RF”) components for the commercial, SATCOM, space and military markets. Its product line ranges from new offerings for the 5G/6G wireless ecosystem and infrastructure, along with quantum computing supporting the United States’ efforts to reach the coveted position of quantum supremacy. Since it was founded back in 2002, AmpliTech has remained committed to research and development (“R&D”), allowing it to remain at the forefront of emerging technologies globally. So far, 2021 has been a great year for AmpliTech, and its management is confident that the trajectory will carry on for the remainder of the year. While making the announcement, Fawad Maqbool, the president, CTO and CEO of AmpliTech, noted: “Our Q2 results reflect initial benefits of our significantly enhanced position and the gradual return of customer prospects to more normal planning and procurement activity for projects where our low noise amplifier solutions can deliver game-changing performance and ROI.” He further added: “Importantly, our financial recapitalization is allowing AmpliTech to engage for the first time with a range of very large customer prospects that were previously out of our reach (https://ibn.fm/7BCnP).” AmpliTech has attributed the impressive 6M’21 performance on expanding sales force efforts and the growing demand for its low noise signal amplifiers. It hopes to further capitalize on this to achieve even faster and additional growth as time progresses. “We are making strategic investments in product development, sales and marketing, and personnel and infrastructure to better position AmpliTech for hyper-growth opportunities we see across several markets, including satellite communications, the build out of true 5G infrastructure, quantum computing and space exploration,” noted Mr. Maqbool (https://ibn.fm/588HQ). The company projects that there will be an unprecedented growth in the demand for wireless connectivity given the proliferation of smart devices, cloud computing, autonomous vehicles and content streaming in the next several years. Its investments so far position it to take advantage of this growth and assert its position as a key infrastructure provider to support 5G, satellite and other radio frequency communications infrastructure. So far, AmpliTech’s investments are bearing fruit, all while laying the foundation for the company’s further growth in the future. For more information, visit the company’s website at www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG